The illustration of protein structure (domains) on the left side, and corresponding exons in the FLT3 gene are displayed on the right side. FMS-like tyrosine kinase 3 (FLT3) mutations represent some ...

– Expanding clinical experience and safety profile of ziftomenib support its evaluation in combination with approved FLT3 inhibitors in frontline AML – – FLT3 mutations occur in approximately 30% of ...

Disruptions in transcriptional regulation during hematopoiesis can lead to abnormal hematopoietic differentiation and the development of leukemia. Understanding the underlying mechanisms of disease ...

Combining proteasome inhibitors with autophagy inhibitors disrupts acute myeloid leukemia (AML) cells' proteostasis, enhancing treatment efficacy and inducing programmed cell death. The novel therapy ...

Investors are also watching the late-stage GPS immunotherapy trial, which is nearing final analysis with 72 of 80 survival ...

Acute myelogenous leukemia (AML), also known as acute myeloid leukemia, is a type of cancer that starts in your bone marrow (the soft, spongy tissue inside the bones that makes blood cells). AML is ...

Treating acute myeloid leukemia (AML) depends on knowing what goes wrong inside cells. A new study suggests that two genetic mutations—IDH2 and SRSF2—work cooperatively to mis-splice RNA messages and ...

Molecular testing is crucial for precision oncology in AML and MDS, but barriers hinder its routine integration. The study analyzed genomic data from 2018 to 2023, focusing on testing rates, types, ...

Compared with white patients, Black patients with acute myeloid leukemia (AML) were on average more than five years younger at diagnosis, more than 30% more likely to die of their disease, and more ...